ABIO vs. AWH, ICCC, VNRX, TKNO, OCX, CDIO, TRIB, ACHV, ELDN, and ZEPP
Should you be buying ARCA biopharma stock or one of its competitors? The main competitors of ARCA biopharma include Aspira Women's Health (AWH), ImmuCell (ICCC), VolitionRx (VNRX), Alpha Teknova (TKNO), OncoCyte (OCX), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Achieve Life Sciences (ACHV), Eledon Pharmaceuticals (ELDN), and Zepp Health (ZEPP). These companies are all part of the "medical" sector.
ARCA biopharma (NASDAQ:ABIO) and Aspira Women's Health (NASDAQ:AWH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, community ranking, media sentiment and valuation.
In the previous week, ARCA biopharma had 4 more articles in the media than Aspira Women's Health. MarketBeat recorded 6 mentions for ARCA biopharma and 2 mentions for Aspira Women's Health. ARCA biopharma's average media sentiment score of 0.39 beat Aspira Women's Health's score of -0.31 indicating that ARCA biopharma is being referred to more favorably in the media.
ARCA biopharma has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Aspira Women's Health has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.
56.4% of ARCA biopharma shares are held by institutional investors. Comparatively, 12.2% of Aspira Women's Health shares are held by institutional investors. 30.9% of ARCA biopharma shares are held by company insiders. Comparatively, 4.3% of Aspira Women's Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
ARCA biopharma received 110 more outperform votes than Aspira Women's Health when rated by MarketBeat users. Likewise, 42.56% of users gave ARCA biopharma an outperform vote while only 29.55% of users gave Aspira Women's Health an outperform vote.
ARCA biopharma has higher earnings, but lower revenue than Aspira Women's Health. ARCA biopharma is trading at a lower price-to-earnings ratio than Aspira Women's Health, indicating that it is currently the more affordable of the two stocks.
ARCA biopharma has a net margin of 0.00% compared to Aspira Women's Health's net margin of -176.74%. ARCA biopharma's return on equity of -16.08% beat Aspira Women's Health's return on equity.
Aspira Women's Health has a consensus price target of $4.45, indicating a potential upside of 38.63%. Given Aspira Women's Health's higher probable upside, analysts plainly believe Aspira Women's Health is more favorable than ARCA biopharma.
Summary
ARCA biopharma beats Aspira Women's Health on 11 of the 16 factors compared between the two stocks.
Get ARCA biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARCA biopharma Competitors List
Related Companies and Tools
